Prescription Monitoring Program (PMP) Public Use Data

Washington’s PMP was created (RCW 70.225 (2007)) to improve patient care and prevent harmful effects with using controlled substance prescription drugs by collecting dispensing records for Schedule II, III, IV and V drugs, and by making the information available to medical providers and pharmacists as a patient care tool. Program rules, WAC 246-470, took effect August 27, 2011. The program started data collection from all dispensers October 7, 2011. This public data only includes dispensations starting from January 1, 2012 to the latest data available.

Under RCW 70.225.040(5)(a), the department is authorized to publish public data after removing information that could be used directly or indirectly to identify individual patients, requestors, dispensers, prescribers, and persons who received prescriptions from dispensers. The data available here are de-identified, and exclude patient, prescriber, and dispenser related information in alignment with program rules WAC 246-470-080. No requestor information is available here.

Prescriptions excluded from the PMP include those dispensed outside of WA State, those prescribed for less than or equal to 24 hours, those administered or given to a patient in the hospital, and those dispensed from a Department of Corrections pharmacy (unless an offender is released with a prescription), an Opioid Treatment Program, and some federally operated pharmacies (Indian Health Services and Veterans Affairs report voluntarily since 2015).

Further information on collection and management of PMP data at DOH can be found at https://doh.wa.gov/public-health-provider-resources/healthcare-professions-and-facilities/prescription-monitoring-program-pmp/data.

Data and Resources

Additional Info

Field Value
Source https://data.wa.gov/resource/8y5c-ekcc
Author WA PMP
Last Updated December 20, 2025, 14:43 (UTC)
Created July 22, 2025, 20:22 (UTC)
1. Tramadol was scheduled as a schedule IV drug in August 2014, and hydrocodone was rescheduled (from III to II) in October 2014.
2. Prescription records displayed use drug information reported by dispensers at the national drug code (NDC) level, supplemented by an internal NDC drug file incorporating multiple data sources (e.g., U.S. FDA NDC Directory and previous Centers for Disease Control and Prevention (CDC) Opioid MME Conversion Files). When available, RxNorm was used to standardize NDC-level drug and drug class fields, ensuring greater consistency across records. RxNorm provides uniform drug naming and links to multiple drug vocabularies widely used in pharmacy management and drug interaction software, including First Databank, Micromedex, Multum, and Gold Standard Drug Database. This integration enhances data consistency and interoperability between different systems. Additionally, RxNorm includes the United States Pharmacopeia (USP) Compendial Nomenclature, which catalogs all Active Pharmaceutical Ingredients (APIs), further improving data accuracy and completeness.
3. Prescription records beginning January 1, 2018 contains an additional 26 variables that were not available in prior years of data.
4. This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product. For more information about RxNorm, please see: Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011 Jul-Aug;18(4)441-8. doi: 10.1136/amiajnl-2011-000116. Epub 2011 Apr 21. PubMed PMID: 21515544; PubMed Central PMCID: PMC3128404.
5. July 1, 2025: Records from 2012Q1 to 2025Q2 were updated for more completeness. Records may not be comparable to previous updates. MME Conversion Factors reflect the 2022 CDC Opioid Prescribing Guidelines Morphine milligram equivalent doses for commonly prescribed opioids for pain management. For more information, please see the following article: Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep 2022;71(No. RR-3):1–95. DOI: http://dx.doi.org/10.15585/mmwr.rr7103a1.
6. November 13, 2025: All records from 2012Q1 to 2025Q2 were revised to correct the animal and non-human animal classification flags. The update affected the following fields: species, human, animal, and prescriberVet. Because of these corrections, current values may not be directly comparable to earlier dataset versions.
Category health
Period of Time 2012Q1-2025Q2 (January 1, 2012 - June 30, 2025)
Posting Frequency Quarterly
harvest_object_id a7af3bd7-e0e9-4acb-afa6-4821407b6ca3
harvest_source_id c4128faf-39ff-4aa3-918e-8a395702cab3
harvest_source_title washington-state